SmokeLess New Zealand

www.smokeless.org.nz  info@smokeless.org.nz  ph 0274 884 375

nasalsnuff.htm                                  Printable version www.smokeless.org.nz/nasalsnuffMay06.pdf

Nasal snuff – a  traditional, less harmful way to use tobacco

The late Dr Michael Russell of London, father of tobacco addiction research:

"Snuff could save more lives and avoid more ill-health than any other preventive measure likely to be available to developed nations well into the 21st century". "Switching from cigarettes to snuff could have enormous health benefits". Snuffing has two major advantages.. Firstly there are no products of combustion such as tar, carbon monoxide and oxides of nitrogen. Secondly it cannot be inhaled into the lungs, which eliminates any risk of lung cancer.1

Professor (Sir) Robert Peto, Oxford University, England, world renowned epidemiologist on smoking:

“If this [snuff dipping] or some other such habit were to become widespread and did to any substantial extent replace smoking (particularly of cigarettes) then the net effect would be likely to be a reduction in tobacco-induced mortality. - 2

 

Nasal snuff is tobacco, ground to the fine dark brown powder seen here. Cigarette companies do not promote snuff – it quells the urge for the next cigarette.

The 4 cm diameter tin is 1 cm in depth, and after removing the sealing tape, contains in its side an oval dispensing slot for tapping out the snuff into the anatomical snuff box (the hollow between the tendons when the thumb is raised vertically in young lean hands) prior to holding the wrist to the nose and sniffing some into each nostril.

This brand of nasal snuff (Super Snuff Singletons Menthol) is made in Germany, and imported by Swedish Match, Auckland for test market sales in New Zealand in 2007.

Switching from smoking to snuffing can reduce the health risks by 90-95%, and financial costs of using tobacco by 60-90%.

________________________________________________________________________________________

Acute effects of use A pinch of tobacco nasal snuff is sniffed up each nostril. For maximum effect, it is sniffed up into the top of the nose, rather than merely sniffing it into the nostrils. Depending on dose, nasal snuff produces tingling, eye watering, a pleasant stinging sensation, a light headedness and some increase in pulse rate, as with smoking a cigarette, in other words, a recognizable nicotine hit, within 2 to 5 minutes. A two-finger pinch in each nostril should suffice. High levels of blood nicotine are achievable with practice. Sneezing is a frequent side-effect.

Nasal snuff takes away the urge to smoke the next cigarette, within 5 minutes. See www.healthnz.co.nz/VASurges.htm 

Legal status. There is no ban on the import or sale of snuff for nasal use in New Zealand (NZ Customs letter to SmokeLess NZ, 2 June 06). Australia has banned snuff at Federal level, and some states have not yet ratified the ban at last count-- South Australia, Western Australia, Tasmania, and Northern Territory. Snuff cannot be advertised in New Zealand.

Ban on sale to under-18s. Section 30 of the Smokefree Environments Act bars sale or supply of tobacco products, including nasal snuff, to under-18s.

Historical status. Nasal snuffing was the most popular way to use tobacco in the 1700s in England and France, especially among upper class men and women, and imported into NZ, mainly from Australia, comprising 0.1% of tobacco imports up to about 1901.

Prevalence of use. A third of Lesotho women have used nasal snuff for many years. See www.smokeless.org.nz/tobaccocancers.htm

Harmful constituents.  TSNAs in Swedish Match products are under 5 ppm, (personal communication, I. Wahlberg, Senior Scientific Officer, Swedish Match,  22 June 2006) and this snuff is no exception. TSNAs may be much higher in some products from other countries.

Price Nasal snuff sold in New Zealand is likely to be less costly than cigarettes or oral snuff. See

www.smokeless.org.nz/snus.htm at Table 1

Tax status In New Zealand, nasal snuff is taxed at the loose tobacco excise rate of 36 cents a gram. [On the basis of low risk,  SmokeLess New Zealand argues that the tax rate should be 5% of the 36 cents per gram loose tobacco rate, that is, 2 cent per gram. (see www.smokeless.org.nz/taxandrisk.htm ]

Nasal snuff is not taxed in the UK.

Price, consumption, use and nicotine intake

In South Africa where snuff was 25% of the price of cigarettes, 13% of black women used snuff, while 5% smoked. Women using nasal snuff sniffed it four times a day, using 50-130 mg of nicotine per day, equal to the nicotine in 20 cigarettes.

Long term risks of use. Quitting smoking is the safest course.  There is little evidence for or against nasal snuff. It is tobacco with virtually the same chemical content as oral snuff, and so is likely to have much the same effects: both are absorbed through mucosa with a rich blood supply. See http://www.smokeless.org.nz/oralsnuff.htm

Chemical content It contains 3.5 g tobacco, making up 63% of its weight, 19% is moisture, 11% paraffin as moisturiser, 4% potassium carbonate to regulate pH, and 3% flavour. See www.smokeless.org.nz/nasalsnuff_analyses.htm Nicotine is 0.7%, that is, 24.5 mg per can.

Risk of nasal cancer.  There is inadequate evidence that nasal use of snuff is carcinogenic to humans. One third of Lesotho women use nasal snuff; less than 1 per 100,000 Lesotho women per year develop nasal pharyngeal cancer.  www.smokeless.org.nz/tobaccocancers.htm

Duration of use A year after stopping smoking, when the danger of relapse to smoking has greatly decreased, nasal snuff takers may wish to switch to nicotine gum or quit nicotine altogether, as nasal snuff has not had a long history of documented relatively-safe and widespread use, as is true for Swedish snuff.

Regulation of purity Nasal snuff in New Zealand is currently not subject to any regulation for purity. In Africa, snuff containing high levels of chromium (24 - 97 ppm) and other metals was suspected to be the cause of high rates of nasal cancer in African people in past years.3 Regulations are needed to bar all snuffs unless low in nitrosamine and heavy metal levels, as are products sourced from Swedish Tobacco or if manufactured from the same tobaccos used in the manufacture of popular New Zealand cigarettes. See Table 2 at www.smokeless.org/snuffregulations.doc  )

Addiction status. Nicotine addiction is common. Smokers take a fairly constant amount of nicotine each day, so smokers who take snuff instead, will smoke fewer cigarettes.  Snuff can and does satisfy smokers’ nicotine needs.

Pharmacology. A single pinch of snuff can raise the nicotine plasma level from 20 ng/mL (due to previous snuffing) to 41ng/mL, an increase of 21 ng/mL within 5 minutes, similar to the  levels found in heavy cigarette smokers - but snuffers attain that peak more rapidly. Nicotine absorption from snuff was faster than by oral absorption from non-inhaled cigar smoke.3 After a single pinch of snuff, occasional snuff users obtain a small (2ng/mL) increase within 8-17 minutes, whereas daily snuff users raised their nicotine level by 12.6 ng/mL, similar to the  nicotine increase from a single cigarette obtained by a heavy smoker.

Singleton Menthol (Swedish Match), as sold in cans of 6 g tobacco in South Africa, contained 1.8% of moisture, 0.6% nicotine by wet weight, 99% of which was in free base form, at a measured pH of 10.1.5 Nicotine delivery is likely to be very high, but plasma nicotine was not measured for this brand. One 6 g can lasts a regular South African user about 3 days.

 

Nasal snuff rivals cigarette smoking in nicotine blood levels attained

Table 1. Plasma nicotine levels attained by nasal snuffers and cigarette smokers

 

Number of subjects

Single pinch of snuff or single cigarette; blood taken 8-17 minutes after

Repeated snuffing or smoking    ng/mL

Average increase ng/mL

Peak value ng/mL

Average increase

Peak values

Occasional snuff users

10

2

 

 

 

Daily snuff users

8

12.6

36.1

54

75.4*

Heavy cigarette smokers

136

10.1

36.7

 

48.1**

*129.3 ng/mL was recorded in one user within 15 minutes

**obtained by rapid smoking

Source: Russell MA. et al. 1981.6

 

Suggested Health warning for nasal snuff

This tobacco product is addictive, can damage your health, and is much less dangerous than smoking

As of March 2007, the New Zealand Ministry of Health did not require any warning.

The following warning, likely to be used in New Zealand meantime, fails to warn of addiction:

This product may be harmful to your health

 

 

Conclusion

For stopping smoking, nasal snuff-taking is a useful option for cigarette smokers who have tried and failed with nicotine patches or gum. The more effective nicotine choices smokers have, the more they are likely to succeed at quitting smoking.

Nasal snuff can be made from cigarette tobacco

Tobacco from any of the ten popular brand cigarettes or cigarette tobacco sold in NZ (except Marlboro) and shown in Table 1 of www.smokeless.org.nz/snuffregulations.htm

conforms to the Swedish Gothiatek standard for snuff. A coffee grinder with a cylindrical burr can convert the cigarette tobacco to the fine powder required. Paraffin, pH buffer, and flavour can be added.

 

Nasal snuff as a second-line stop smoking aid

A case can be made for recommending that smokers not successful with nicotine patch and gum, try nasal snuff as a second-line stop-smoking aid.

As risk of nasal snuff use is likely to be similar to that of oral snuff (about 1 less survivor per 1000 previous smokers who  switch to snuff at age 50-54 compared with quitting entirely6) and as nasal snuff is legal to sell in New Zealand, Smokeless New Zealand believes that…

health professionals have a duty to inform smokers that

     1) nicotine products provide the safest stop- smoking method

     2) snuffing, though not risk-free, is much less dangerous than smoking. Switching to snuff will reduce a smoker’s risks substantially. See www.smokeless.org.nz/switchingtosnuff.htm

 

1 . Russell MA, Jarvis MJ, Feyerabend C. A new age for snuff? Lancet 1980; 1: 474-5.

2. Peto R. Control of tobacco-related disease. In: The value of preventive medicine. Ciba Foundation Symposium 110. London: Pitman 1985 pp.126-142.

3. International Agency for Research on Cancer (IARC). Tobacco Habits other than smoking. 1985 v. 37, p.37. Last updated 21 April 1998.

4. Shapiro MP, Keen P, Cohen L, De Moor NG Malignant disease in the Transvaal. III Cancer of the respiratory tract. South African Med J 1955; 29: 96-101..

5. Ayo-Yusuf OA, Swart TJP, Pickworth WB. Nicotine delivery capabilities of smokeless tobacco products and implications for control of tobacco dependence in South Africa. Tob Control 2004; 13: 186-9.

6. Russell MAH, Jarvis MJ, Devitt G. Feyerabend C. Nicotine intake by snuff users. Br Med J 1981;283: 814-7.

7. See www.smokeless.org.nz/switchingtosnuff.htm

Dr Murray Laugesen QSO chair; Prof Ross McCormick, Sir John Scott KBE,  Trish Fraser MPH, Trustees

<

Advocating better options for smokers and an end to cigarette sales © SmokeLess New Zealand